The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis

Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to several Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved medications that slow disease progression by immunomodulatory a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vališ, Martin, Achiron, Anat, Hartung, Hans Peter, Mareš, Jan, Tichá, Veronika, Štourač, Pavel, Halusková, Simona, Angelucci, Francesco, Pavelek, Zbyšek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676342/
https://www.ncbi.nlm.nih.gov/pubmed/37640862
http://dx.doi.org/10.1007/s40268-023-00434-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676342/
https://www.ncbi.nlm.nih.gov/pubmed/37640862
http://dx.doi.org/10.1007/s40268-023-00434-6

Ejemplares similares